On Thursday, January 26th, the University of Chicago Comprehensive Cancer Center at Little Company of Mary Hospital (LCMH) unveiled its new radiation oncology Philips Brilliance CT Big Bore with a special blessing ceremony. This advanced technology assists the radiation oncologist with treatment accuracy, patient positioning, and imaging performance. The Center, located on LCMH’s main campus in Evergreen Park, will offer radiation therapy techniques not typically available in a community setting.
Dr. Azhar Awan is the medical director of the Cancer Center’s radiation oncology department and was most recently recognized in Chicago Magazine’s Top Cancer Doctors special issue. He is excited about the benefit to patients this technology offers with the 4DCT and tumor tracking. This offers the ability to track the tumor movement during the patients breathing cycles allowing precise treatment to the tumor while sparing surrounding tissue.
In April of 2016, the two hospitals jointly announced the formation of the University of Chicago Medicine Comprehensive Cancer Center at LCMH. Under this affiliation agreement, the University of Chicago Medicine will bring its cancer care, academic specialists and array of clinical trials to the LCMH Evergreen Park campus under a new affiliation agreement. UChicago Medicine’s Comprehensive Cancer Center at LCMH will offer outpatient services, including an infusion center, radiation therapy, specialty clinic services and clinical trials. The Center brings all aspects of medical cancer care together to offer promising new treatments and a continuum of care, from diagnosis through survivorship.
“We are proud to partner with the University of Chicago Medicine,” said Dennis Reilly, President and CEO of LCMH. “This partnership enhances our oncology services so that we may be an even greater resource for our community. By bringing together our primary and secondary expertise and UChicago Medicine’s advanced subspecialty care, our community won’t have to travel as far to receive specialized cancer care or participate in state-of-the-art clinical trials.”